Capricor Therapeutics (CAPR) Receivables (2015 - 2025)

Capricor Therapeutics' Receivables history runs 4 years deep, the most recent figure standing at $59167.0 for Q4 2025.

• In Q4 2025, Receivables fell 99.71% year-over-year to $59167.0; the TTM figure through Dec 2025 stood at $59167.0 (down 99.71% YoY), while the FY2024 annual figure was $20.0 million, changed 0.0% from the prior year.
• Receivables was $59167.0 for Q4 2025 at Capricor Therapeutics, down from $20.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $20.4 million in Q4 2024 to a low of $59167.0 in Q4 2025.
• Historically, Receivables has averaged $13.5 million across 3 years, with a median of $20.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables increased 1.84% in 2024, then slumped 99.71% in 2025.
• A 3-year view of Receivables shows it stood at $20.0 million in 2023, then grew by 1.84% to $20.4 million in 2024, then plunged by 99.71% to $59167.0 in 2025.
• The last three Receivables figures came in at $59167.0 (Q4 2025), $20.4 million (Q4 2024), and $20.0 million (Q4 2023), per Business Quant data.